Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03472547 · ClinicalTrials.gov registry record · Phase 1

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

A Phase 1 study of Healthy, sponsored by Castle Creek Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
234
Enrollment target
1
Study location

NCT03472547 is a Phase 1 study of Healthy that has completed, run by Castle Creek Pharmaceuticals. The registered enrollment target is 234 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03472547, a Phase 1 study of Healthy, has completed, sponsored by Castle Creek Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
234 participants
Enrollment target
1
Study location

Study Summary

Single center, randomized, controlled, evaluator blinded, within-subject study to evaluate the sensitization potential of diacerein 1% ointment under occlusive conditions on normal skin of healthy volunteer subjects.

Conditions Studied

Interventions

  • DRUG diacerein 1% ointment

Study Locations (1)

New Jersey

  • TKL Research - Fair Lawn

Trial Details

FieldValue
Enrollment Target 234 participants
Start Date 2018-01-15
Est. Completion 2018-03-03
Phase Phase 1

Sponsor

Castle Creek Pharmaceuticals

7 total trials

What the Registry Record Tells You About NCT03472547

The ClinicalTrials.gov registry entry for NCT03472547 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (64% lower). The listed sponsor is Castle Creek Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which diacerein 1% ointment is the first listed.

NCT03472547 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT03472547 about?

NCT03472547 is a clinical study titled "A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects". Single center, randomized, controlled, evaluator blinded, within-subject study to evaluate the sensitization potential of diacerein 1% ointment under occlusive conditions on normal skin of healthy volunteer subjects.

What is the current status of trial NCT03472547?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 234 participants. The study started on 2018-01-15. Estimated completion is 2018-03-03.

What conditions does trial NCT03472547 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT03472547?

The interventions under investigation include: diacerein 1% ointment (DRUG).

Who is sponsoring clinical trial NCT03472547?

This trial is sponsored by Castle Creek Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03472547 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.